Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity
| العنوان: | Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity |
|---|---|
| المؤلفون: | Esther Oomen-de Hoop, Leni van Doorn, Anne Lenting, Ferry A.L.M. Eskens, Sander Bins, Ron H.N. van Schaik, Samira El Bouazzaoui, Ron H.J. Mathijssen |
| المساهمون: | Medical Oncology, Clinical Chemistry |
| المصدر: | Pharmacogenomics, 17(14), 1483-1490. Future Medicine Ltd. |
| بيانات النشر: | Future Medicine Ltd, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, Niacinamide, 0301 basic medicine, Oncology, Sorafenib, medicine.medical_specialty, Genotype, Abcg2, Antineoplastic Agents, Pharmacology, Polymorphism, Single Nucleotide, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Genetics, Humans, Medicine, Glucuronosyltransferase, Aged, Retrospective Studies, biology, Liver-Specific Organic Anion Transporter 1, business.industry, Phenylurea Compounds, Liver Neoplasms, Middle Aged, medicine.disease, Multidrug Resistance-Associated Protein 2, digestive system diseases, Diarrhea, 030104 developmental biology, Treatment interruption, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Toxicity, biology.protein, Molecular Medicine, Female, medicine.symptom, business, SLCO1B1, Pharmacogenetics, medicine.drug |
| الوصف: | Aim: Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib. Patients & methods: We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherlands, for SLCO1B1, SLCO1B3, ABCC2, ABCG2, UGT1A1 and UGT1A9. Results: The UGT1A1 (rs8175347) polymorphism was associated with hyperbilirubinemia and treatment interruption. Polymorphisms in SLCO1B1 (rs2306283, rs4149056) were associated with diarrhea and thrombocytopenia, respectively. None of the investigated polymorphisms was associated with overall or progression-free survival in hepatocellular cancer patients. Conclusion: Polymorphisms in SLCO1B1 and UGT1A1 are associated with several different sorafenib side effects. |
| تدمد: | 1744-8042 1462-2416 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c97956b7127fa39e9116d1ccee26e59Test https://doi.org/10.2217/pgs-2016-0063Test |
| حقوق: | RESTRICTED |
| رقم الانضمام: | edsair.doi.dedup.....4c97956b7127fa39e9116d1ccee26e59 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17448042 14622416 |
|---|